News und Analysen
![Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new Dexcom ONE Continuous Glucose Monitoring System will
![Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new Dexcom ONE Continuous Glucose Monitoring System will
![Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005765/en/
Dr. Alessandro Riva (Photo: Transgene)
Transgene
![Waters Introduces Xevo TQ Absolute – The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Waters Introduces Xevo TQ Absolute – The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer
Waters Corporation (NYSE:WAT) today introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class.i
This press release features multimedia
![STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that the U.S. Food and Drug
![Waters präsentiert eine schnellere, zuverlässigere und automatisierte Lösung für die Massen- und Reinheitsanalyse von Biomolekülen](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Waters präsentiert eine schnellere, zuverlässigere und automatisierte Lösung für die Massen- und Reinheitsanalyse von Biomolekülen
Die Waters Corporation (NYSE:WAT) stellte heute neue Software und analytische Säulen zur Unterstützung der Erforschung und Entwicklung von Biomolekülen vor. Mit der neuen App 'Intact Mass' von
![Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity Analysis of Biomolecules](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity Analysis of Biomolecules
Waters Corporation (NYSE:WAT) today introduced new software and analytical columns to aid biomolecule drug discovery and development. The new Waters™ Intact Mass app on waters_connect™ allows
![Dexcom G7 erhält CE-Kennzeichnung – Das kontinuierliche Blutzuckermesssystem der nächsten Generation wird das Diabetesmanagement revolutionieren](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Dexcom G7 erhält CE-Kennzeichnung – Das kontinuierliche Blutzuckermesssystem der nächsten Generation wird das Diabetesmanagement revolutionieren
DexCom, Inc. (NASDAQ:DXCM), der weltweit führende Anbieter im Bereich der kontinuierlichen Blutzuckermessung in Echtzeit für Menschen mit Diabetes, gab heute bekannt, dass das Unternehmen die
![Dexcom G7 erhält CE-Kennzeichnung – Das kontinuierliche Blutzuckermesssystem der nächsten Generation wird das Diabetesmanagement revolutionieren](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Dexcom G7 erhält CE-Kennzeichnung – Das kontinuierliche Blutzuckermesssystem der nächsten Generation wird das Diabetesmanagement revolutionieren
DexCom, Inc. (NASDAQ:DXCM), der weltweit führende Anbieter im Bereich der kontinuierlichen Blutzuckermessung in Echtzeit für Menschen mit Diabetes, gab heute bekannt, dass das Unternehmen die
![Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark (Conformité Européenne) for the Dexcom G7
![Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark (Conformité Européenne) for the Dexcom G7
![Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
Alacer Corp. today announced the launch of Natean®, a new eco-conscious oral healthcare brand providing products to consumers looking for nature-inspired toothpastes that deliver essential oral
![Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
Alacer Corp. today announced the launch of Natean®, a new eco-conscious oral healthcare brand providing products to consumers looking for nature-inspired toothpastes that deliver essential oral
![Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), is pleased to announce that effective March 14 2022, the Ontario government will provide coverage
![Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), is pleased to announce that effective March 14 2022, the Ontario government will provide coverage
![Humana Launches CenterWell Home Health](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Humana Launches CenterWell Home Health
One year after launching the CenterWell brand to represent Humana’s payer-agnostic healthcare service offerings, Humana Inc. (NYSE: HUM) has started to transition Kindred at Home’s home health
![Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure’s Founder and Chief Technology Officer, has been selected to receive the 2022 Israel Prize in the field of entrepreneurship and
![NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial unveiling of the CosMx™ Spatial
![Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq:
![Humana Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Humana Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index
Leading health insurer and health care services company Humana Inc. (NYSE: HUM), proudly announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality
![Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes who are under 18 years old and require ongoing use of
![Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes who are under 18 years old and require ongoing use of
![Waters Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Waters Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index
Waters Corporation (NYSE:WAT) announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and
![GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220123005091/en/
Figure 1. Evolution of BCVA In LUMEVOQ®-treated
![argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005641/en/
Tim Van Hauwermeiren, co-founder and CEO of argenx